Dr. Weber on Dabrafenib/Trametinib Versus Vemurafenib/Cobimetinib in Melanoma
November 25th 2015
Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program, head of Experimental Therapeutics, NYU Langone Medical Center, compares the efficacy of dabrafenib plus trametinib versus vemurafenib plus cobimetinib.